Treats major depressive disorder (MDD). ANDA 204003, held by Alembic. Desvenlafaxine Succinate.
As of Nov 22, 2026, ANDA 204003 (Desvenlafaxine Succinate), held by Alembic, was first approved by FDA on Jun 29, 2015, with 6 approved supplements and 0 published complete response letters.
Desvenlafaxine is indicated for the treatment of adults with major depressive disorder (MDD).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 29, 2015 | Original application | Approved |
| Desvenlafaxine SuccinateEQ 50MG BASE · tablet, extended release;oral | Desvenlafaxine Succinate | Rx |
| Desvenlafaxine SuccinateEQ 100MG BASE · tablet, extended release;oral | Desvenlafaxine Succinate | Rx |
| Desvenlafaxine SuccinateEQ 25MG BASE · tablet, extended release;oral | Desvenlafaxine Succinate | Rx |
| Aug 16, 2024 | Supplement 26Labeling · Standard review | Approved | None posted |
| Jan 23, 2023 | Supplement 19Labeling · Standard review | Approved | None posted |
| Jan 23, 2023 | Supplement 20Labeling · Standard review | Approved | None posted |
| Mar 4, 2019 | Supplement 6Labeling · Standard review | Approved | None posted |
| Apr 27, 2017 | Supplement 3Labeling · Standard review | Approved | None posted |
| Apr 27, 2017 | Supplement 4Labeling · Standard review | Approved | None posted |
| Jun 29, 2015 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters